However, blood ILC2s from severe asthma patients treated with mepolizumab, an anti‐IL‐5 biologic, exhibited reduced receptor expression for IL‐7 (i.e., CD127), TSLP, IL‐25 (i.e., IL‐17RB) and PGD2 (i.e., CRTH2) [192]. This evidence concerns the gene IL5 and asthma.